MHRA Recalls Novartis Cough and Cold Medicine

News
Article

Agency issues precautionary recall due to manufacturing fault.

The Medicines and Healthcare products Regulatory Agency (MHRA) issued a recall on certain batches of Novartis Consumer Health UK Ltd’s Tixylix cough and cold medicines because of a possible fault in the manufacturing process of the tamper seal that might result in small pieces of plastic being found in the liquid medicines. MHRA says that there is no evidence, as of yet, of problems occurring as a result of this manufacturing fault but they are recalling the drugs as a precautionary measure.

“This is a precautionary recall and there is currently no evidence that people have had any problems with these medicines,” said Adam Burgess, the MHRA’s Head of Defective Medicines Reporting Centre (DMRC), in a press release.“If people have bought Tixylix we ask that they check the batch number on the bottle label next to the expiry date to see if it is one of the batches being recalled. If anyone has an affected batch they should return it to the place of purchase for a refund. If people do have any questions they can contact Novartis on 0800 854 100 or visit tixylix.co.uk.”

Specific batches of the Tixylix medicines being recalled by Novartis include:
Tixylix Toddler Syrup 100mL (Glycerol)—PL 00030/0150
Tixylix Toddler Syrup 150mL (Glycerol)—PL 00030/0150
Tixylix Baby Syrup 100mL (Glycerol)—PL 00030/0150
Tixylix Blackcurrant Flavour Syrup 100mL (Glycerol)—PL 00030/0150
Tixylix Chesty Cough 100mL (Guaifenesin)—PL 00030/0082

Source: MHRA

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments